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Background: Post stroke cognitive impairment (PSCI) occurs commonly and is linked with 
development of dementia. It is not clear whether acute stroke factors are associated with 
development of PSCI. We investigated the relationship between cardiovascular risk factors, stroke 
symptoms and presence of PSCI at 1 and 3 years after stroke. 
Methods: We accessed anonymised data from the Virtual International Stroke Trial Archive (VISTA), 
including demographic and clinical variables. PSCI was defined as a Mini Mental State Examination 
(MMSE) score of ≤26. We assessed univariate relationships between baseline stroke symptoms and 
PSCI at 1 and 3 years following stroke, retaining the significant and relevant clinical factors as 
covariates in a final adjusted logistic regression model.  
Results: We analysed data on 5435 patients. Mean (±SD) age was 62.6 (±12.6) years, 3476 (65%) 
patients were male. Follow up data were available for 2270 and 1294 at one and three years, 
respectively. After adjusting for age, stroke severity, hypertension, diabetes and type of qualifying 
event, initial stroke impairment (leg paralysis) was associated with increased rate of PSCI at one year 
(OR=1.62; 95% CI=1.20-2.20) and at three years (OR=1.95; 95% CI=1.23-3.09). Associations were 
consistent on subgroup analysis restricted to ischaemic stroke and transient ischaemic attack 
(N=4992).  
Conclusions: Early clinical features are associated with development of PSCI up to 3 years after 
















Post stroke cognitive impairment (PSCI) represents an important subset of patients with VCI, 
and refers to patients who develop cognitive deficits after a stroke. Cognitive impairment 
related to cerebrovascular causes can further progress to dementia1 which affects up to a 
third of stroke patients and represents one of the main causes of functional dependency2,3 
and mortality after stroke4. Identification of factors associated with PSCI may be valuable to 
prevent progression of cognitive deficits.  
Pendlebury and Rothwell identified demographic and vascular factors as well as imaging 
features associated with incident dementia after stroke5. Characteristics of the stroke event 
are also associated with subsequent development of PSCI. Severe clinical stroke deficits at 
onset are associated with higher risk of PSCI6,7. No differences have been found between 
hemorrhagic and ischemic stroke in causing PSCI, although the different survival rate may 
lead to estimation bias3. Moreover, it has been hypothesized that some stroke deficits could 
per se lead to PSCI. Pohjasvaara et al. suggested that aphasia and dominant stroke 
syndrome are associated with post stroke dementia8. However, aphasia is commonly 
mistaken for PSCI, and even though language represents a cognitive domain, aphasia should 
not be considered as a surrogate of PSCI. Moreover, relationship between clinical stroke 
features of the acute event (i.e. stroke symptoms) and cognitive performance are less well 
described.  
The aim of the present study was to investigate the associations between demographical, 
clinical and stroke features and PSCI in patients with a stroke or transient ischemic attack.  
Methods 
We conducted a retrospective analysis of individual patient level data from the Virtual 
International Stroke Trial Archive (VISTA). VISTA is an academic collaboration which provides 
access to existing patient trial data to perform exploratory analyses with the aim to help 
planning and design of future clinical trials9. Ethical approval was not required since data 
were anonymised. Our study population included patients with any type of brain vascular 
event, including ischaemic stroke, hemorrhagic stroke, transient ischaemic attack (TIA). 
Clinical variables of interest included age, sex, hypertension, diabetes, atrial fibrillation, 
ischaemic heart disease, hypercholesterolemia, depression (history of), cigarette smoke 
exposure. Functional status at baseline was assessed with the Oxford Handicap Scale 
(OHS)10. Baseline stroke symptoms included arm paralysis, leg paralysis, sensory deficit, 
aphasia, neglect, hemianopia dichotomized as presence/absence at stroke onset. All 
patients underwent global assessment to define stroke subtype, including radiological 
exams (CT or MR), extensive blood tests, thoracic and neck vessels imaging and cardiac 
assessment where appropriate.  
Cognitive function on survivals at one and three years was assessed on voluntary basis using 
MMSE, defining cognitive impairment as a score of MMSE≤2611. 
We described characteristics of study population at baseline, one and three years. 
Furthermore, we described the differences in baseline characteristics of patients for whom 
MMSE was available and for whom this was not using χ2 for categorical variables, two-
sample t-test for normally distributed variables and Mann-U Whitney test for non-
parametric distributions. 
We tested univariate associations between cognitive impairment and age, sex, baseline 
OHS, hypertension, diabetes, arm paralysis, leg paralysis, aphasia, neglect, sensory 
impairment, hemianopia. We retained significant variables (p<0.1) from the univariate 
analysis in a multivariate logistic regression. We adjusted the analysis for clinical relevant 
factors such as history of depression and type of brain vascular event. Variables with p<0.05 
were considered independent predictors of outcomes. Furthermore, we performed 
subgroup analysis in patients with defined diagnosis of ischaemic stroke and TIA. We 
accounted for the presence of potential interaction between statistically significant stroke 
symptoms and functional status at baseline in our multivariate analysis. Analysis was carried 
out by using SPSS for Windows (version 22.0; SPSS, Armonk NY, IBM Corp.).   
Results 
Data at baseline were available for 5453 patients, 3476 (65%) were male, mean age (±SD) 
was 62.5 (±12.5) years. Median time to baseline assessment was 33 days (IQR=8-88) after 
the qualifying event. After one year, 129 (2.4%) of patients died, and 323 (5.9%) died within 
3 years. As to stroke type, 3970 (73%) of patients had ischaemic stroke as qualifying event, 
around one fifth (1022, 19%) had TIA and 461 (8%) had haemorrhagic stroke (Fig.1).  
Table 1 shows baseline characteristics of study population. The majority of patients were 
functionally independent, with a median OHS of 1 (IQR=1-2). Hypertension was the most 
frequent cardiovascular risk factor (71%). About two thirds of patients had either arm or leg 
paralysis, whereas cortical symptoms such as neglect were less frequent (8%). 
At one and three years follow up data on MMSE were available for 2270 (41.6%) and 1294 
(23.7%) patients, respectively. Patients for whom MMSE scores were available were older 
(p<0.001 at one and three years) and more likely to have less disability at baseline (p<0.001 
at one and three years). They also had fewer neurological impairment such as aphasia (23% 
vs 29% at one year, p<0.001; 20% vs 28% at three years, p<0.001) neglect (6% vs 9% at one 
and three years, p<0.001), arm paralysis (63% vs 73% at one year, p<0.001; 63% vs 71% at 
three years, p<0.001) and limb paralysis (53% vs 65% at one year, p<0.001; 53% vs 63% at 
three years, p<0.001) (Suppl. Tab.1 and suppl. tab.2). At one year, 781 (34%) patients had 
MMSE≤26, at three years 391 (30%) had MMSE≤26.  
After any brain vascular event age, female sex, stroke severity at baseline, diabetes were 
independently associated with poorer MMSE at both one and three years (Tab.2). Leg 
paralysis was also associated with MMSE≤26 at both time points (OR=1.62; 95% CI=1.20-2.20; 
OR=1.95; 95% CI=1.23-3.09 respectively). Arm paralysis was associated with poorer PSCI only 
at one year (OR=1.46; 95% CI=1.06-2.02). There was no interaction between limb paralysis 
and functional status. Aphasia was associated with PSCI at three years (OR=1.56; 95% 
CI=1.15-2.11); however, this association was confounded by interaction with OHS at 
baseline (p=0.018) (Suppl. tab.3). Subgroup analysis for ischaemic events (ischaemic strokes 
and TIA) confirmed age, female sex, stroke severity and diabetes as independently 
association with poorer cognitive performance at one and three years. Hypertension was 
also associated with cognitive impairment at three years. Leg paralysis remained associated 
with MMSE≤26 at both one and three years (OR=1.54; 95% CI=1.15-2.07; OR=1.82; 95% 
CI=1.16-2.85) (Tab.3), with no interaction with functional status at baseline. Aphasia was 
associated with cognitive impairment at one year (OR=1.35; 95% CI=1.06-1.72) and at three 
years (OR=1.78; 95% CI=1.26-2.53), but at three years there was evidence of interaction 
with functional status at baseline (p=0.028) (Supp. Tab.3). Neglect, hemianopia and sensory 
impairment were not associated with cognitive impairment at one and three years in both 
stroke groups.   
Discussion 
We investigated the associations between baseline stroke symptoms and post stroke 
cognitive impairment defined as MMSE≤26. As defined by this cut-off, in our cohort around 
one third of patients with stroke in the long term had cognitive impairment. Age, female 
sex, stroke severity, history of diabetes were associated with PSCI at one and three years 
and in all study groups. Among stroke symptoms, paralysis in the lower limb at baseline was 
consistently associated with PSCI.  
Our results regarding age, female sex, diabetes are in keeping with previous studies3,5 that 
demonstrated an increased risk of cognitive deficits after stroke. We found that 
hypertension was associated with PSCI after three years only in the ischemic stroke 
subgroup, this result is in line with the aforementioned Pendlebury and Rothwell 
metanalysis5.  
Interestingly, we found that leg paralysis at baseline appeared to be independently 
associated with cognitive impairment at both follow up time points. In addition, we 
observed a lack of interaction between leg paralysis and functional status at baseline. Gait 
problems may independently predict disability or death12 and risk of both cognitive 
impairment and dementia13,14. In a population cohort study, hemiparetic gait has been 
associated both to vascular and non-vascular dementia14. A recent prospective study found 
that gait impairment after mild stroke increased the risk of developing cognitive decline 
after two years15.  Assuming leg paralysis as a surrogate of gait dysfunction, our results are 
in keeping with such association.  
In our study, aphasia increased the risk of cognitive impairment one year after ischaemic 
stroke/TIA, although associations at three years were confounded by interaction with 
functional status at baseline. We acknowledge that aphasia could negatively affect the 
assessment of cognitive status with MMSE, which relies on the language ability of the 
patient16. Since language is a cognitive domain, language deficits represent a subset of 
cognitive impairment, therefore this result needs to be interpreted with caution.    
We acknowledge shortcomings that may have biased our results. First, the non-systematic 
assessment of cognitive function at follow up may have lead to an attrition bias. Although 
we found low mortality rates, our supplemental tables showed that selection likely favoured 
those with less neurological impairment. The higher rates of baseline symptoms such as 
paralysis or aphasia in patients without cognitive assessment at follow up seem to confirm 
that an attrition bias occurred. However, this fact may have underestimated rather than 
overestimate our results reducing the rate of patients with cognitive impairment17. 
Moreover, diagnosis of PSCI should be based on a comprehensive evaluation including a 
complete multi-domain neuropsychological battery.  Use of a brief dementia screening tool, 
such as MMSE, is not a substitute for formal neuropsychological and clinical assessment. 
However, in the context of a multicentre clinical trial with many thousands of patients there 
is a necessary trade-off between diagnostic detail and feasibility. MMSE is a reasonable tool 
for detection of post stroke dementia and is commonly used in practice as well as in 
research.  
Although a recent systematic review highlighted that MMSE is more specific than other 
screening tests for detection of cognitive impairment11, the lack of sensitivity of the 
MMSE≤26 cut-off may underestimate the real prevalence of cognitive impairment18,19. 
Together with attrition bias, it seems likely that the prevalence of cognitive impairment 
after stroke is higher than we reported. 
In conclusion, in our sample of patients with mild stroke, around 30-34% of patients 
experienced cognitive impairment between one and three years. We confirmed increasing 
age, female sex, stroke severity, history of diabetes as factors associated with PSCI. Among 
stroke features, leg paralysis may predict cognitive impairment in the long term follow up. 
Early detection of mobility impairment after stroke may help to identify patients at risk of 
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Age, mean (±SD) 62.6 (±12.6) 64.1 (±11.9) 63.7 (±11.8) 
Sex, male 3476 (64) 1515 (65) 848 (65) 
OHS baseline, median (IQR) 1 (1-2) 1 (1-2) 1 (1-2) 
Hypertension 3890 (71) 1664 (72) 925 (70) 
Diabetes 1321 (24) 543 (23) 298 (22) 
Ischaemic heart disease 928 (17) 397 (17) 201 (15) 
Atrial fibrillation 420 (8) 179 (8) 98 (8) 
Hypercholesterolemia 2299 (42) 1094 (47) 615 (47) 
Smoker 1310 (24) 537 (23) 268 (20) 
Depression 437 (8) 211 (9) 115 (9) 
Arm paralysis 3753 (69) 1452 (63) 826 (63) 
Leg paralysis   3310 (61) 1228 (53) 687 (52) 
Aphasia/dysarthria 1438 (26) 541 (23) 261 (20) 
Neglect  436 (8) 145 (6) 75 (6) 
Sensory impairment 1780 (33) 732 (32) 462 (35) 
Hemianopia  519 (10) 199 (9) 103 (8) 







Table 2. Associations between baseline stroke symptoms and cognitive impairment (MMSE≤26) in all 
brain vascular events (ischaemic, TIA, haemorrhagic). Analysis adjusted for all the variables listed in 
the table. 
 All stroke subtypes 
One year CI Three years CI 
 Unadjusted OR (95%CI) Adjusted OR (95%CI) Unadjusted OR (95%CI) Adjusted OR (95%CI) 
Age 1.03 (1.02-1.03) 1.03 (1.02-1.04) 1.04 (1.03-1.05) 1.04 (1.03-1.06) 
Sex, female 1.53 (1.28-1.84) 1.49 (1.22-1.80) 1.95 (1.53-2.50) 1.78 (1.37-2.31) 
OHS baseline 1.71 (1.53-1.91) 1.38 (1.23-1.56) 1.53 (1.32-1.78) 1.30 (1.10-1.54) 
Hypertension 1.35 (1.11-1.65) 1.09 (0.88-1.35) 1.68 (1.27-2.22) 1.25 (0.93-1.68) 
Diabetes 1.74 (1.43-2.13) 1.57 (1.27-1.94) 2.14 (1.63-2.82) 1.86 (1.38-2.50) 
Arm paralysis 1.93 (1.60-2.33) 1.46 (1.06-2.02) 1.41 (1.09-1.81) 0.97 (0.60-1.59) 
Leg paralysis 2.10 (1.75-2.51) 1.62 (1.20-2.20) 1.74 (1.37-2.23) 1.95 (1.23-3.09) 
Aphasia 1.24 (1.01-1.51) 1.24 (0.96-1.60) 1.63 (1.23-2.17) 1.67 (1.17-2.40)* 
Neglect 1.13 (0.79-1.60) - 0.97 (0.58-1.62) - 
Sensory impairment 0.90 (0.75-1.09) - 0.82 (0.64-1.05) - 
Hemianopia 1.30 (0.96-1.76) - 1.25 (0.81-1.91) - 
 
CI=Cognitive impairment; OR=odds ratio; CI=Confidence Interval.   









Table 3. Associations between baseline stroke symptoms and cognitive impairment (MMSE≤26) in 
ischaemic events (ischaemic stroke and TIA). Analysis adjusted for all the variables listed in the table. 
 Ischemic stroke/TIA 
One year CI Three years CI 
 Unadjusted OR (95%CI) Adjusted OR (95%CI) Unadjusted OR (95%CI) Adjusted OR (95%CI) 
Age 1.03 (1.02-1.04) 1.03 (1.02-1.04) 1.04 (1.03-1.06) 1.04 (1.03-1.06) 
Sex, female 1.72 (1.40-2.12) 1.57 (1.27-1.96) 2.09 (1.59-2.77) 1.86 (1.38-2.50) 
OHS baseline 1.49 (1.33-1.68) 1.33 (1.18-1.51) 1.40 (1.20-1.64) 1.24 (1.04-1.48) 
Hypertension 1.47 (1.17-1.85) 1.24 (0.97-1.58) 1.89 (1.37-2.62) 1.43 (1.01-2.03) 
Diabetes 1.68 (1.35-2.10) 1.60 (1.27-2.02) 2.32 (1.71-3.13) 2.15 (1.56-2.97) 
Arm paralysis 1.80 (1.44-2.25) 1.30 (0.96-1.77) 1.37 (1.02-1.84) 0.81 (0.51-1.29) 
Leg paralysis 1.95 (1.58-2.40) 1.54 (1.15-2.07) 1.71 (1.29-2.27)   1.86 (1.19-2.92) 
Aphasia 1.40 (1.12-1.76) 1.35 (1.06-1.72) 1.79 (1.30-2.48) 1.81 (1.28-2.57)* 
Neglect 1.13 (0.78-1.65) - 0.93 (0.54-1.61) - 
Sensory impairment 0.99 (0.81-1.23) - 0.84 (0.63-1.11) - 
Hemianopia 1.27 (0.91-1.76) - 1.36 (0.86-2.16) - 
CI=Cognitive impairment; OR=odds ratio; CI=Confidence Interval.                                                         
*p for interaction with functional status=0.028. 
 
 
 
